Get the Stockscreener App
2.20
3.77%
0.08
Vivos Therapeutics Inc stock is traded at $2.20, with a volume of 79,013.
It is up +3.77% in the last 24 hours and down -20.29% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$2.12
Open:
$2.14
24h Volume:
79,013
Relative Volume:
0.30
Market Cap:
$19.77M
Revenue:
$14.58M
Net Income/Loss:
$-12.57M
P/E Ratio:
-0.3873
EPS:
-5.68
Net Cash Flow:
$-13.07M
1W Performance:
-5.98%
1M Performance:
-20.29%
6M Performance:
+5.77%
1Y Performance:
-25.42%
1-Day Range:
$2.10
$2.23
1-Week Range:
$2.10
$2.50
52-Week Range:
$1.98
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
2.20 | 15.91M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Vivos Therapeutics Inc Stock (VVOS) Latest News
Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges - MSN
Why Vivos Therapeutics Inc. stock remains on buy lists2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2025 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $5.44 Average Target Price from Analysts - Defense World
Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift - MSN
Published on: 2025-11-20 02:04:52 - newser.com
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth By Investing.com - Investing.com Nigeria
Vivos Therapeutics signals continued revenue acceleration amid SCN integration and SAMC expansion plans - MSN
Vivos Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Why Vivos Therapeutics Inc. stock appeals to analystsFed Meeting & Technical Confirmation Alerts - newser.com
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth - Investing.com India
What technical charts say about Vivos Therapeutics Inc. stockWeekly Gains Summary & Verified Entry Point Signals - newser.com
Vivos Therapeutics Rides Acquisition Wave To Higher Revenue - Finimize
[8-K] Vivos Therapeutics, Inc. Reports Material Event | VVOS SEC FilingForm 8-K - Stock Titan
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 - The Globe and Mail
Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition - MarketScreener
Vivos Therapeutics (NASDAQ: VVOS) reports 78% third quarter revenue growth - Stock Titan
[10-Q] Vivos Therapeutics, Inc. Quarterly Earnings Report | VVOS SEC FilingForm 10-Q - Stock Titan
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Vivos Therapeutics, Inc. Plans Q3 2025 Financial Results Release and Investor Conference Call - Quiver Quantitative
Vivos Therapeutics (NASDAQ: VVOS) to Release Q3 2025 Results, Host Call Today - Stock Titan
Vivos Therapeutics (NASDAQ:VVOS) Coverage Initiated at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Vivos Therapeutics (VVOS) with Buy Recommendation - Nasdaq
Vivos Therapeutics (VVOS) Receives New Coverage From HC Wainwrig - GuruFocus
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
HC Wainwright Initiates Vivos Therapeutics at Buy With $7 Price Target - MarketScreener
Vivos Therapeutics Delays Q3 Report Amid Acquisition - MSN
Is Vivos Therapeutics Inc. stock a safe haven asset2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
What institutional flow reveals about Vivos Therapeutics Inc.Weekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
Can Vivos Therapeutics Inc. stock surprise with earnings upside2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
How risky is Vivos Therapeutics Inc. stock now2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Will Vivos Therapeutics Inc. continue its uptrend2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
Is Vivos Therapeutics Inc. stock undervalued vs historical averagesTrade Exit Summary & Stepwise Swing Trade Plans - newser.com
How supply chain issues affect Vivos Therapeutics Inc. stock2025 Price Targets & Free Technical Confirmation Trade Alerts - newser.com
Exit strategy if you’re trapped in Vivos Therapeutics Inc.Weekly Trade Analysis & Accurate Technical Buy Alerts - newser.com
Vivos Therapeutics files for non-timely 10-Q with US SEC - MarketScreener
[NT 10-Q] Vivos Therapeutics, Inc. SEC Filing - Stock Titan
Will Vivos Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & Weekly Breakout Watchlists - Fundação Cultural do Pará
Vivos Therapeutics, Inc. (VVOS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Will Vivos Therapeutics Inc. see short term momentumWeekly Stock Analysis & Weekly Top Gainers Trade List - newser.com
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):